Effects of atrial fibrillation screening according to thyroid function: Post-hoc analysis of the randomized LOOP study.

Atrial fibrillation implantable loop recorder oral anticoagulation stroke thyrotropin

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
04 Sep 2024
Historique:
received: 19 06 2024
revised: 16 08 2024
accepted: 30 08 2024
medline: 4 9 2024
pubmed: 4 9 2024
entrez: 4 9 2024
Statut: aheadofprint

Résumé

Subclinical thyroid dysfunction is a marker for atrial fibrillation (AF) and stroke risk. This study explored the effects of AF screening according to thyroid-stimulating hormone (TSH) levels. An AF screening trial (the LOOP study) was analyzed post-hoc according to baseline TSH. The primary outcome was stroke or systemic embolism (SE). Secondary outcomes included major bleeding, all-cause death, and the combination of stroke, SE, and cardiovascular death. TSH measurement was available in 6003 of 6004 trial participants, 1500 randomized to implantable loop recorder (ILR) screening for AF and anticoagulation upon detection vs. 4503 to usual care; mean age was 74.7±4.1 years and 2836 (47%) were women. AF detection was approximately triple for ILR vs usual care across TSH tertiles (adjusted p-interaction=0.44). In the first tertile, screening was associated with decreased risk of the primary outcome (hazard ratio 0.52 [0.30-0.90]; p=0.02) and stroke, SE, or cardiovascular death (hazard ratio 0.54 [0.34-0.84]; p=0.006) compared to usual care, while no effect was observed among participants with higher TSH (adjusted p-interaction 0.03 and 0.01, respectively). There was no effect on other outcomes. Analyses of continuous TSH or excluding those with abnormal TSH or thyroid medication showed similar results. AF screening and subsequent treatment was associated with decreased stroke risk among participants with low TSH, though the yield of screening was similar across TSH levels. TSH may be useful as a marker to indicate benefit from AF screening vs. overdiagnosis and overtreatment. These findings should be considered exploratory and warrant further study. ClinicalTrials.gov, identifier: NCT0203645.

Identifiants

pubmed: 39231015
pii: 7749353
doi: 10.1210/clinem/dgae610
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00203645']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.

Auteurs

Daniel Camillo Spona (DC)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.

Diana My Frodi (DM)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.

Lucas Yixi Xing (LY)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.

Emilie Katrine Kongebro (EK)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.

Ketil Jørgen Haugan (KJ)

Department of Cardiology, Zealand University Hospital Roskilde, Sygehusvej 10, 4000 Roskilde DENMARK.

Claus Graff (C)

Department of Health Science and Technology, Aalborg University, Selma Lagerløfs Vej 249, 9260 Gistrup, DENMARK.

Søren Højberg (S)

Department of Cardiology, Copenhagen University Hospital - Bispebjerg, Bispebjerg Bakke 23, 2400 Copenhagen DENMARK.

Derk Krieger (D)

Stroke Unit, Mediclinic City Hospital, Building 37 - 26th St, Dubai, UAE.

Axel Brandes (A)

Department of Cardiology, Odense University Hospital, J. B. Winsløws Vej 4, 5000 Odense, DENMARK.
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Finsensgade 35, 6700 Esbjerg, DENMARK.
Department of Cardiology, Esbjerg Hospital - University Hospital of Southern Denmark, Finsensgade 35, 6700 Esbjerg, Denmark.

Lars Køber (L)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, DENMARK.

Morten S Olesen (MS)

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Blegdamsvej 3B, 2200 Copenhagen, DENMARK.

Andreas Andersen (A)

Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark, Borgmester Ib Juuls Vej 83, 2730 Herlev, Denmark.

Sofie Hædersdal (S)

Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark, Borgmester Ib Juuls Vej 83, 2730 Herlev, Denmark.

Ruth Frikke-Schmidt (R)

Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, DENMARK.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, DENMARK.

Jesper Hastrup Svendsen (JH)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, DENMARK.

Søren Zöga Diederichsen (SZ)

Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Inge Lehmanns Vej 7, 2100 Copenhagen, DENMARK.

Classifications MeSH